Concepedia

Author

Gilberto de Castro

Instituto do Câncer do Estado de São PauloORCID

Also Known As

Castro G, Castro Junior, Gilberto de, D Castro, Dalvaro Oliveira Castro Junior, Dalvaro Oliveira de Castro Junior, G Castro, G de Castro, G de Castro Jr, G. Castro, G. Castro Jr

476

Publications

33.6K

Citations

53

H-Index

78

Concepts

All Affiliations

Instituto do Câncer do Estado de São PauloUniversidade de São PauloMerck & Co., Inc., Rahway, NJ, USA (United States)Vall d'Hebron Hospital UniversitariHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
GD

About

Gilberto de Castro is an author at Instituto do Câncer do Estado de São Paulo specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

33

57

21.3K

2

Health Sciences

15

20

9K

3

Public Health

2

2

35

4

Cell Biology

1

1

63

5

Diabetes

1

1

12

Gilberto de Castro

×

107

Publications

21.1K

Citations

45

H-Index

YearCitations

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst, Paul Baas, Dong‐Wan Kim,

The Lancet

2015

6.4K

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba,

The Lancet

2019

3.2K

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil,

The Lancet

2019

3K

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari,

The Lancet

2017

1.1K

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

David Cameron, Martine Piccart, Richard D. Gelber,

The Lancet

2017

1K

Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30

Kim Cocks, Madeleine King, Galina Velikova,

European Journal of Cancer

2012

522

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

Kevin J. Harrington, Barbara Burtness, Richard Greil,

Journal of Clinical Oncology

2022

438

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Jean-Pascal H. Machiels, Robert I. Haddad, Jérôme Fayette,

The Lancet Oncology

2015

386

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

Gilberto de Castro, Iveta Kudaba, Yi‐Long Wu,

Journal of Clinical Oncology

2022

281

Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies

Kaname Nosaki, Hideo Saka, Yukio Hosomi,

Lung Cancer

2019

274

Page 1